A Prospective Study on Predictive Value of Absolute Eosinophil Count for Bronchodilator Reversibility in COPD Patients

  • Deepak Kumar Kalra Associate Professor, Department of TB & Respiratory Diseases, Subharti Medical College, Meerut, U.P, India.
Keywords: COPD, PREDICTIVE VALUE, BRONCHODILATOR REVERSIBILITY, EOSINOPHILIC COPD, NON- EOSINOPHILIC COPD

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) patients are prone to exacerbation that account for significant morbidity and mortality. According to physio-pathologic and clinical-functional viewpoints, bronchiectasis and COPD have some common characteristics, it has been observed that bronchiectasis was present in up to 50% of patients with moderate to severe COPD . This observation suggests that COPD is a risk factor for bronchiectasis.

METHODOLOGY: This study was included 120 totals who were attending the OPD in the department of TB Chest. This study was conducted in the Department of TB & Respiratory Diseases, Shri Dev Suman Subharti Medical College, Dehradun.

RESULT: In our study we were included 120 total number of cases, out of all cases 35.5% cases were found from eosinophilic COPD group & 62.5% were found non-eosinophilic COPD group. In eosinophilic COPD group,42 male and 3 females were found. While in non-eosinophilic COPD group ,60 male and 15 females were found.

CONCLUSION: This study suggested that flow reversibility associated with this volume reversibility was more in eosinophilic COPD.

Downloads

Download data is not yet available.

References

1. T.A.R. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, J.A. Wedzicha, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med. 157 (1998) 1418–1422.
2. R.A. Stockley, Neutrophils and the pathogenesis of COPD, Chest 121 (Suppl. 5) (2002) 151S–155S.
3. S. Fuschillo, A. De Felice, G. Balzano, Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms, Eur. Respir. J. 31 (2) (2008) 396–406.
4. National Collaborating Center for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 (Suppl. 1) (2004) 1–232.
5. M.A. Martinez-Garcia, J.J. Soler-Cataluna, M. Perpina- Tordera, P. Roman-Sanchez, J. Soriano, Factors associatedwith lung function decline in adults patients with stable noncystic fibrosis bronchiectasis, Chest 132 (5) (2007) 1565–1572.
6. I.S. Patel, I. Vlahos, T.M.A. Wilkinson, et al, Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med. 170 (4) (2004) 400–407.
7. C.O. O’Brien, P.J. Guest, D.L. Hill, R.A. Stockley, Physiological and radiological characteristaion of patients diagnosed with chronic obstructive pulmonary disease in primary care, Thorax 55 (8) (2000) 635–642.
8. H. Cabello, A. Torres, R. Celis, M. El-Elbiary, J. Puig de la Bellacassa, A. Xaubet, J. Gonzalez, C. Agusti, N. Soler, Bacterial Colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study, Eur. Respir. J. 10 (1997) 1137–1144.
9. S. Sethi, T.F. Murphy, Bacterial infection in chronic obstructive pulmonary disease in 2000: a state of the art review, Clin. Microbiol. Rev. 14 (2001) 336–363.
10. I.S. Patel, T.A.R. Seemungal, M. Wilks, S.J. Lloyd-Owen, G.C. Donaldson, J.A. Wedzicha, Relationship between bacterial colonization and the frequency, character and severity of COPD exacerbations, Thorax 57 (2002) 759–764.
11. A.E. O’Donnell, Bronchiectasis Chest 134 (4) (2008) 815–823.
12. Bronchiectasis; NICE CKS, August 2010 .
13. Guideline for non-CF Bronchiectasis; British Thoracic Society (July 2010).
14. O'Donnell AE; Bronchiectasis. Chest. 2008 Oct;134(4):815-23.
15. King PT, Holdsworth SR, Freezer NJ, et al; Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006 Dec;100(12):2183-9. Epub 2006 May 2.
16. Ten Hacken NH, van der Molen T; Bronchiectasis. BMJ. 2010 Jul 14;341:c2766. doi: 10.1136/bmj.c2766.
17. Murray MP, Hill AT; Non-cystic fibrosis bronchiectasis. Clin Med. 2009 Apr;9(2):164-9.
18. Philips MS, Willliams MP, Flower CD. How useful is computed tomography in the diagnosis and assessment of bronchiectasis? ClinRadiol 1986;37:321-5.
19. Grenier P, Maurice F, Musset D, Menu Y, Nahum H. Bronchiectasis: assessment by thin-section CT, Radiology 1986; 161:95-9.
20. Foreman K, Lim S, Shibuya K, Aboyans D,Lozano R, Naghavi M et al., Global and regional mortality from 235 causes of death for 20 agegroups in 1990 and 2010: A systemic analysis for the global burden of the disease study 2010. Lancet 2012; 380: 2095-128.
21. Orie NGM, Sluiter HJ, De Vries K, Tammeling GJ, Witkop J. The host factor in bronchitis. In: Orie NGM, Sluiter HJ, Editors Royal Vangorcum, Assen: Bronchitis. 1961; 43–59..
22. Dahlen I, Janson C, Bjornsson E, Stalenheim G, Peterson CG,Venge P. Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respir Med 2001; 95: 891–897
23. Chanez P, Vignola AM, O’Shaugnessy T et al. Corticosteroid reversibility in COPD is related to features of asthma. AmJ Respir Crit Care Med 1997; 155: 1529–1534.
24. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J RespirCrit Care Med 1995; 152: 1666–1672.
25. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med1997; 155: 449–453.
26. Frew AJ, Kennedy SM, Chan-Yeung. Methacholine responsiveness, smoking and atopy as risk factors for accelerated FEV1 decline in male working populations. Am Rev Respir Dis 1992; 146: 878–883.
27. Gottlieb DJ, Sparrow D, O’Connor GT, Weiss ST. Skin test reactivity to common aeroallergens and decline of lung function:the Normative Aging Study. Am J Respir Crit Care Med 1996; 153:561–566.
28. Villar MTA, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1: a longitudinal study in the elderly. Am J Respir Crit Care Med 1995; 151: 656–662..
29. O Connor GT, Sparrow D, Weiss ST. The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139: 225–252.
Published
2019-09-30
How to Cite
1.
Kalra DK. A Prospective Study on Predictive Value of Absolute Eosinophil Count for Bronchodilator Reversibility in COPD Patients. Int Arch BioMed Clin Res [Internet]. 2019Sep.30 [cited 2019Oct.24];5(3):65-7. Available from: https://www.iabcr.org/index.php/iabcr/article/view/502
Section
ORIGINAL ARTICLES ~ Pulmonary Medicine